Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort

Canadian Journal of Gastroenterology

Volumn 23, Issue 5, 2009, Pages 348-352

  Teshima, Christopher W ^a   Thompson, Adrienne ^a   Dhanoa, Le Rose ^a   Dieleman, Levinus A ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clinical practice; Crohn's disease; Immunosuppression; Infliximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; COLON SURGERY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAW DISEASE; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOPLASM; OSTEOMYELITIS; OUTPATIENT CARE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RASH; REVIEW; SERUM SICKNESS; TREATMENT DURATION; TUBERCULOSIS; ARTICLE; COLONOSCOPY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; OUTPATIENT; REMISSION; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLONOSCOPY; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTPATIENTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649922530     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/180840     Document Type: Review

References (24)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with crohn's disease. N Engl J Med 1999;340:1398-405.
3. D'Haens G, Baert F, van Assche G, et al. Early combined, immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial, Lancet 2008;371:660-7.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
5. Sands BE, Anderson TH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
6. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary experience. Am J Gastroenterol 2000;95:3469-77.
7. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 2001;96:722-9.
8. Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn's disease: One-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6.
9. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63.
10. Wenzl HH, Reinisch W, Jahnel J, et al. Austrian infliximab experience in Crohn's disease: A nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 2004;16:767-73.
11. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
12. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episode treatment for the healing of mucosal ulceration associated with Crohn's disese. Gastrointest Endosc 2006;63:433-42.
13. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
14. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm county. Gut 2004;53:849-53.
15. Lichtenstein GR, Feagan BG, Cohen Rb, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
16. Panaccione R, Fedorak RN, Aumais G, et al. Canadian association of gastroenterology clinical practice guidelines: The use of infliximab in Crohn's disease. Can J Gastroenterol 2004;18:503-8.
17. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
18. Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol 1988;41:451-8.
19. Fedorak RN, Bitton A, Hassard P, et al. Infliximab dose in real-life remains stable over 30 months with favourable benefit: Risk profile in CD. Gastroenterology 2007;132(S2):A180.
20. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
21. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dis Sci 2008;53:1033-41.
22. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: Results from a single centre cohort. Gut 2009;58:492-500.
23. Sandborn W, Rugeerts P, Reinisch W, et al. SONIC: A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunosuppressives and biologic therapy [late breaking abstract]. Am J Gastroenterol 2008;103(S1):1117.
24. Feagan BG, McDonald J, Ponich T, et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD) [late-breaking abstract]. Gastroenterology 2008;134(S1):682c.